Verastem (VSTM) risk factors
Item 1A of every Verastem, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors67 risks11 new5 dropped13 reworded
Verastem successfully transitioned to commercializing AVMAPKI FAKZYNJA CO-PACK following accelerated approval for recurrent LGSOC.
Filed Mar 04, 2026 - FY2024 10-K risk factors61 risks
Verastem carries heavy financial risk with $955.5 million in accumulated deficit, a new $150.0 million debt facility, and required going concern evaluations. The company faces high regulatory hurdles for clinical trials and commercialization of its lead oncology candidates, avutometinib and defactinib. Reliance on third-party manufacturers, clinical investigators, and licensing partners like Pfizer and Chugai exposes the pipeline to external failures.
Filed Mar 20, 2025